Pfizer Adopts Accolade

Sopheon PLC
09 July 2003


Immediate Release: 9th July 03

                                  Sopheon Plc
                                  ('Sopheon')

   Pfizer Adopts Sopheon's Accolade Product Development System to Strengthen
                     Post-Commercialization Product Support

MINNEAPOLIS and LONDON - July 8, 2003 - Sopheon, the international software and
services company, announced today that a division of Pfizer, the world's leading
research-based pharmaceutical company, has begun using the capabilities of
Sopheon's flagship Accolade product development system to enable the reuse of
product knowledge in support of commercialized products. Sales and marketing
professionals and product physicians at Pfizer locations throughout Malaysia and
Singapore are employing Accolade's functionality to enhance the provision of
up-to-date product information to customers and prospects.


Malini Tharumalingam, business technology director of Pfizer Malaysia-Singapore,
said: 'Accolade acts as a centralized, easily accessible repository that enables
us to supply our customers with timely and accurate information on our products.
The system has added substantial value to our business.'


Sopheon's Accolade automates gate- or phase-based product development processes
and allows companies to improve innovation, cut product development waste and
shorten time to market. The system organizes documents, resources and metrics;
facilitates team communication; and provides access to the internal and external
information and human expertise necessary to inform decision-making throughout
the product lifecycle.


'Most product lifecycle management (PLM) solutions are designed as if
development stops when a product is launched,' said Chris Hawver, chief
marketing officer of Sopheon. 'One of Accolade's principal advantages is its
ability to strengthen innovation and product development by facilitating the
transfer and reuse of product knowledge and intelligence. We believe that this
type of functionality is critical because it closes the loop that connects the
birth and development of a product idea to its commercialization, continued
evolution, retirement and, finally, the inception of the next-generation
offering. It's our opinion that this capacity for cradle-to-grave process
support is a standard by which the viability of future PLM solutions will be
measured. Pfizer's application of Accolade is one more step in that direction.'


About Pfizer

Pfizer Inc. (NYSE: PFE) discovers, develops, manufactures and markets leading
prescription medicines for humans and animals, including many of the world's
best-known consumer brands. The company has three business segments: health
care, animal health and consumer health care. Its products are available in more
than 150 countries. For more information, please visit www.pfizer.com.


About Sopheon

Sopheon (LSE:SPE) is an international provider of software tools, experts and
content that help organizations improve the business impact of product
development. Sopheon enables clients to achieve higher, faster return on
innovation and product development investments through technology and
human-based decision support. The company's products and services include its
flagship Accolade(R) product development system and Knowledge Network (formerly
Organik(R)) expertise-sharing software. Sopheon is listed on the AIM market of the
London Stock Exchange and on the Euronext in the Netherlands. For more
information, please visit www.sopheon.com.


Press Contacts

Ron Helgeson

Sopheon

Tel.: [phone]

E-mail: [e-mail]


Katy Brennan

LNS Communications

Tel.: [phone]

E-mail: [e-mail]



                      This information is provided by RNS
            The company news service from the London Stock Exchange